Applied Dna Sciences (NASDAQ:BNBX – Get Free Report) and Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.
Profitability
This table compares Applied Dna Sciences and Sagimet Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Applied Dna Sciences | -1,647.25% | -349.95% | -283.96% |
| Sagimet Biosciences | N/A | -31.96% | -30.57% |
Earnings and Valuation
This table compares Applied Dna Sciences and Sagimet Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Applied Dna Sciences | $2.09 million | 0.34 | -$15.16 million | ($3.33) | -0.03 |
| Sagimet Biosciences | $2.00 million | 251.78 | -$51.04 million | ($1.28) | -6.33 |
Applied Dna Sciences has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Applied Dna Sciences, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Applied Dna Sciences has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.46, meaning that its share price is 246% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Applied Dna Sciences and Sagimet Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Applied Dna Sciences | 1 | 0 | 0 | 0 | 1.00 |
| Sagimet Biosciences | 2 | 1 | 9 | 0 | 2.58 |
Sagimet Biosciences has a consensus price target of $26.63, indicating a potential upside of 228.78%. Given Sagimet Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than Applied Dna Sciences.
Insider and Institutional Ownership
22.2% of Applied Dna Sciences shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 6.1% of Applied Dna Sciences shares are held by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Sagimet Biosciences beats Applied Dna Sciences on 11 of the 14 factors compared between the two stocks.
About Applied Dna Sciences
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company’s supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
About Sagimet Biosciences
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Receive News & Ratings for Applied Dna Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Dna Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
